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Abstract
Purpose The influence of pregnancy on uterine fibroid size still remains an unsolved dilemma. Basing on current knowledge, 
physicians are not able to inform patients about the likelihood of uterine fibroids to modify their size during pregnancy. 
Study aim was to summarize available evidence concerning the size modifications of uterine fibroids during each trimester 
of pregnancy and during puerperium.
Methods The review was reported following the PRISMA guidelines and registered in PROSPERO (registration number: 
CRD42017071117). A literature search was conducted in electronic database (PubMed, Embase, Sciencedirect, the Cochrane 
library and Clinicaltrials.gov) until July 2017. All studies evaluating fibroids’ changes during pregnancy and puerperium by 
ultrasound or magnetic-resonance-imaging were included. Descriptive characteristics of studies and patients were collected. 
The modifications of uterine fibroid diameter and volume were the outcome measures.
Results Concerning the first trimester of pregnancy, all authors reported a significant growth of uterine fibroids. Contradic-
tory evidence was found about uterine fibroid modifications during the second and third trimesters, mainly supporting a 
slowdown during mid pregnancy and a subsequent size reduction during late pregnancy. Concerning the overall modifications 
during pregnancy and puerperium, poor evidence quality suggests that uterine fibroids do not modify their volume/slightly 
enlarge during pregnancy and subsequently reduce in size during puerperium.
Conclusions Uterine fibroids seem to be subject to a non-linear trend of modifications during pregnancy and puerperium, 
which may vary from myoma to myoma. Adequate evidence supports uterine fibroid systematic enlargement during the first 
trimester of pregnancy, while inconsistent evidence is available about the changes of uterine fibroids during second and third 
trimesters. In addition, the overall modifications of myomas during pregnancy and puerperium remain unclear.
Keywords Uterine fibroids · Fibroid size · Size modifications · Pregnancy · Puerperium
Introduction
Uterine fibroids (UFs), also known as myomas or leio-
myomas, are benign monoclonal neoplasms of the smooth 
muscle layer of uterus [1, 2]; they represent the most com-
mon benign gynecological tumors in young women, with a 
prevalence increasing with age from 40 to 60% at 35 years 
to 70–80% at 50 years old [3].
Despite their benign histological features, UFs have con-
siderable economic and social impacts, being the most com-
mon clinical indication to hysterectomy in USA and repre-
senting a possible cause of hospitalization and complications 
during pregnancy [2, 4, 5]. As a matter of fact, UFs affect up 
to 10.7% of pregnant women and in 10–30% of cases may be 
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responsible of major adverse outcomes, mainly when large 
[5, 6]. Obstetric complications related to UFs include early 
and late miscarriage, preterm birth, fetal malpresentation, 
placental abruption, post-partum hemorrhage, and higher 
risk of cesarean delivery [6, 7]. Moreover, principally dur-
ing the early pregnancy, UFs may cause bulky symptoms 
or severe abdominal pain due to myoma degeneration or 
torsion, especially in case of pedunculated UF. In selected 
situations, when leiomyomal cell necrosis and peritoneal 
reaction occur, performing an urgent myomectomy may be 
the unique therapeutic option for pelvic pain unresponsive 
to analgesia [5, 8].
The influence of pregnancy on UFs size is debated for up 
to 3 decades and still remains an unsolved dilemma: whilst 
some authors concluded that these neoplasms are likely to be 
subject to significant increase of size during gestation; other 
authors state that their volume remains unchanged or even 
decreased during the course of pregnancy [9–11].
The objective of our systematic review is to analyze all 
the available evidences about the changes of UFs’ size dur-
ing pregnancy.
Materials and methods
Study design
This is a systematic review of the size modifications of UFs 
during each trimester of pregnancy and during puerperium.
The review was reported following the Preferred Report-
ing Items for Systematic Reviews and Meta-Analyses 
(PRISMA) guidelines [12].
Study registration
The systematic review was registered in PROSPERO 
before to start the literature search (registration number: 
CRD42017071117).
Inclusion criteria
• Population: Pregnant women with UFs as diagnosed by 
ultrasound (US) and/or magnetic-resonance imaging 
(MRI).
• Intervention: Two or more following measurements of 
UFs.
• Comparator: None.
• Timing: From pre-gestational age to puerperium.
• Outcomes: Assessment of UFs’ size modifications at each 
stage of pregnancy and after birth.
• Study designs: Observational studies (prospective, retro-
spective, and non-concurrent cohort studies, case–control 
studies, case series). We will include both full reports and 
data from conference abstracts describing observational 
studies.
• Language: Only studies reported in English language.
Search strategy
A systematic literature search was conducted in electronic 
database (PubMed, Embase, Sciencedirect, the Cochrane 
library, and Clinicaltrials.gov) until July 2017 without date 
restriction.
The search used specific key words and database index-
ing terminology. The key search terms included: uterine 
fibroids OR uterine myomas OR uterine leiomyomas modi-
fication OR enlargement OR reduction (Mesh/Emtree) AND 
pregnancy OR first trimester of pregnancy OR second tri-
mester of pregnancy OR third trimester of pregnancy OR 
puerperium.
Study selection and data extraction
Two authors (A.V. and M.N.) independently screened titles 
and abstracts of studies obtained by the search strategy. The 
text of each potentially relevant study was obtained and 
assessed for inclusion in each section of the review, inde-
pendently by the two authors. A manual search of reference 
lists of retrieved studies and available review articles was 
successively performed to avoid missing relevant publica-
tions. The same authors (A.V. and M.N.) also independently 
extracted data from studies about study features (design, 
setting, objectives, and main findings), population charac-
teristics (age, ethnicity, inclusion criteria, and gestational 
age at recruitment), UFs measures (diameter and volume), 
and timing of UFs’ measurements. If more than one study 
was published for the same cohort with identical endpoints, 
the report containing the most comprehensive information 
on the population was included to avoid overlapping popu-
lations. One other author (C.S.) independently reviewed 
the selection and data extraction process. The results were 
compared, and any disagreement discussed and resolved by 
consensus.
According to the different endpoints of our study 
(reported below), each manuscript was systematically 
evaluated for inclusion in each section of our review on the 
basis of the time interval in which UFs modifications were 
investigated (first trimester, second trimester, third trimester, 
puerperium, and entire pregnancy).
Endpoints of the systematic review
We settled five endpoints according to the precise period 
of pregnancy in which UFs modifications were evaluated: 
modifications of UFs during the first trimester of pregnancy; 
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modifications of UFs during the second trimester of preg-
nancy; modifications of UFs during the third trimester of 
pregnancy; modifications of UFs during the puerperium; 
overall modifications of UFs induced by pregnancy.
Data synthesis and analysis
We reported all descriptive characteristics of study includ-
ing study design, year of publication, study setting, type and 
number of patients, and size and number of UFs evaluated. 
The modifications of UFs diameter (cm) and volume  (cm3) 
were the measures of effect for this systematic review.
Since there was a marked heterogeneity among studies 
in the timing of UFs measurement and outcome measures 
reported, a quantitative data synthesis was not performed.
Risk of bias
The methodological quality of each study was indepen-
dently assessed by two authors (A.V. and M.N.) with Qual-
ity Assessment Tool for Before–After (Pre–Post) Studies 
with No Control Group (available at https://www.nhlbi.
nih.gov/health-pro/guidelines/in-develop/cardiovascular-
risk-reduction/tools/before-after) that considers 12 “yes/
no” items and gives one point for each affirmative answer. 
This quality assessment tool was used to estimate the abil-
ity of each study to draw associative conclusions about 
the effects of exposure (specific timeframes of pregnancy 
and puerperium) on outcome (size modifications of UFs). 
Studies were considered with poor, fair, and good quality 
rating, respectively, if scoring less than 4 points, between 4 
and 7 points, and at least 8 points. Disagreements between 
reviewers were resolved through discussion and adjudica-
tion of a third reviewer (C.S.).
Results
Study selection
The literature search based on our pre-defined key search 
item identified 3233 publications, after removing dupli-
cates. The titles of these manuscripts were screened, 
resulting in 86 studies considered potentially eligible to be 
included in the review. Of the total of relevant manuscripts 
identified, 70 studies were excluded after the examina-
tion of the abstracts and 16 studies were further evaluated. 
After the evaluation of full text, four studies were addi-
tionally excluded: two manuscripts were review articles 
[8, 13]; one study assessed exclusively the prevalence of 
UFs in pregnancy without evaluating their modifications 
[10]; one additional study [14] potentially reported dupli-
cation of data included in another study [15]. Finally, we 
identified nine full-text manuscripts [9, 10, 15–21] and 
three congress abstract [22–24] eligible for this systematic 
review after applying our inclusion and exclusion criteria 
(see Fig. 1).
Fig. 1  PRISMA flow diagram
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Included studies
Twelve studies with a total of 807 participants were 
included in this systematic review. Seven were prospec-
tive cohort studies [9, 10, 15, 17, 19, 23, 24], one was a 
prospective controlled study [16], three were retrospective 
studies [18, 20, 21], and one was a case series [22]. In all 
studies, the measurements of UFs were performed with 
US, except for Laughlin et al. [10] who used MRI exclu-
sively to confirm UFs modifications (previously evaluated 
by US) during puerperium. All general characteristics of 
studies are summarized in Table 1.
Type of patients
Ethnicity: Two studies evaluated only white women [9, 
19]. Two additional studies included mainly white women 
(respectively, 89.1% in Muram et  al. [20] and 62% in 
Laughlin et al. study [10]. Lev-Toaff et al. [17] and Ham-
moud et al. [18] evaluated mainly black women (respec-
tively, 79.6 and 89.4%). The remaining studies did not 
provide data about ethnicity [15, 16, 21–24].
Parity: Patients were mainly nulliparous in five studies 
(respectively, 87.2% [9], 78.9% [18], 64% [16], 61% [21], 
and 57.1% [19]). In one study, half were nulliparous and 
half pluriparous [10], while in the remaining studies, par-
ity was not reported [15, 17, 20, 22–24].
Type of fibroids
Minimum size evaluated: Three studies [15, 20, 21] ana-
lyzed only UFs with mean diameter greater than 30 mm. 
Three other studies [9, 16, 19] evaluated all UFs with 
mean diameter greater than 10 mm (< 50 mm in diameter 
in Benaglia et al. [16] and Ciavattini et al. [9] studies). 
Other studies did not report clear data about the minimum 
mean UFs diameter evaluated [10, 17, 18, 22–24].
Position: UFs were mainly located in corpus uteri in 
all studies [9, 10, 17, 19–21] providing data, especially 
in anterior wall (51.2 and 66% in Winer-Muram [21] and 
De Vivo studies [19]), mainly in posterior wall (55.2%) in 
Ciavattini et al. study [9]. Remaining studies did not report 
data [15, 16, 18, 22–24].
UFs subtype: Intramural and subserosal were the main 
UFs evaluated in the two studies [9, 19] reporting clear 
data (90.5% intramural and 9.5% subserosal in De Vivo 
et al. study [19]; 50% intramural and 50% subserosal in 
Ciavattini et al. study [9]). In addition, Laughlin et al. [10] 
evaluated the correlations between UFs subtype and their 
modifications (without providing data about the number 
of UFs subtypes evaluated). The majority of the authors 
[15–18, 20–24] did not provide data.
Modifications of uterine fibroids
According to variety of information provided by the authors, 
five studies [10, 16, 20, 22, 23] were included exclusively in 
one section, three studies in two sections [9, 21, 24], three 
studies in three sections [17–19], and one study in five sec-
tions [15].
Main findings and qualitative modifications of UFs are 
reported in Table 2 and illustrated in Fig. 2.
First trimester of pregnancy
Four studies [9, 15–17] evaluated UFs modifications during 
the first trimester of pregnancy. In the majority of studies [9, 
15, 16], patients received the first UFs measurement before 
conception (1 month before IVF cycle [16], within 4 months 
[9] or 1 year [15] before conception), except for Lev-Toaff 
et al. [17] study, in which timing of UFs measurements was 
not reported. Ciavattini et al. [9] performed US twice at 7–8 
and 10–13 gestational weeks (GW), Rosati et al. [15] every 
2–4 weeks during the whole first trimester, while Lev-Toaff 
et al. [17] and Benaglia et al. [16] only once during the first 
trimester.
In all studies, a trend of growth of UFs was found. In 
Benaglia et  al.’s experience [16], a significant increase 
in mean diameter (+ 34%; from 17 ± 10 to 23 ± 13 mm, 
p < 0.001) and median volume of UFs was reported (+140%; 
from 1.6 mL [0.5–5.5] to 5.2 mL [1.4–14.7]) in the initial 
pregnancy (until 6–7 GW), involving all UFs independently 
from their initial size [16]. Similarly, a significant growth in 
median diameter and median volume was reported by Cia-
vattini et al. [9] at 7–8 GW US (respectively, from 18 mm 
[12–25] to 25 mm [18–30] and from 3.1 cm3 [0.9–8.2] to 
8.2 cm3 [3–14.1]; p < 0.01), with a further increase at the 
second US evaluation at 10–13 GW (up to 31 mm [27–40] 
in diameter and to 15.6 [10.3–33.5] in volume, p < 0.01). 
In agreement with other authors [9, 16], Rosati et al. [15] 
reported a significant increase in UFs volume during the first 
trimester (+ 8.21% in comparison to pre-pregnancy volume), 
as well as Lev-Toaff et al. [17] observed a mean increase 
in UFs diameter during such period, even if not significant 
(probably due to small sample size evaluated: 17 UFs).
Second trimester of pregnancy
UFs modifications during such period were investigated by 
five studies [9, 15, 17–19]. In the majority of studies [9, 15, 
18, 19], timing of UFs’ measurement was clearly described, 
except in Lev-Toaff et al. paper [17].
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De Vivo et al. [19] observed a significant increase of 
mean UFs volume between the first (11.6 ± 0.5 GW) and 
second US scan (20.6 ± 0.4 GW), from 17.04 ± 29.1 cm3 
at the first scan to 38.8 ± 67.8 cm3 at the second scan 
(p = 0.006). Similarly, Ciavattini et al. [9] reported a sig-
nificant increase of UFs size between 10 and 13 and 20 and 
22 GW (from 15.6 cm3 [10.3–33.5] to 24.4 cm3 [10.3–35.1], 
p < 0.01), even if lower in comparison to UFs enlargement 
during the first trimester (mean increase + 2.6 vs + 8.5 cm3 
during the first trimester).
Differently, in two other studies [17, 18], a variable 
pattern of growth of UFs was reported. In particular, 
Hammoud et al. [18] observed that almost half of UFs 
reduced in size (55.1%) and half increased in size (44.9%) 
in the interval between 16 and 19 and 20 and 30 GW, with 
a pooled median reduction of UFs volume (from 56.38 to 
45.08 cm3, p = 0.001). In addition, Lev-Toaff et al. [17] 
observed two different trends of size changes according to 
the initial fibroid size: among small fibroids (< 6 cm mean 
diameter), the 30.3% increased in size, and the 14.5% 
decreased in size, while in the group of large fibroids 
(≥ 6 cm mean diameter), the 13.8% increased in size and 
48.3% decreased in size (quantitative data not provided). 
Finally, Rosati et al. [15] reported a slight increase of UFs 
Table 2  Main findings of the included studies
a Study in abstract form
b Evaluated with average diameter modifications
c Outcome measure not reported
d Modifications expressed in volume modifications
Study ID Main findings
Muram et al. (1980) In 38/41 myomas, no change in size during pregnancy was observed. In two cases, diameter increased of 20 and 
25%, whilst in one patient, a reduction of 20% in diameter was  foundb
Winer-Muram et al. (1983) In 82/89 of the patients, there was no change in the size of myoma from the first ultrasound to pregnancy term; in 
6, there was an increase in size (by up to 4 cm in diameter); and in 1 case, the neoplasm decreased in diameter by 
2 cm. All the 31 patients available for rescanning 6-week post-partum showed a marked decrease in the size of the 
 myomasb
Lev-Toaff et al. (1987) During the first trimester, regardless of original size, myomas enlarged (n = 17). During second trimester, the 
fashion was dependent to original size of lesions (small myomas: 30.3% increased and 14.5% decreased; large 
myomas 48.3% decreased and 13.8% increased). During the third trimester, a general size reduction was found 
(34.8% of small myomas and 58.8% of large myomas)b
Aharoni et al. (1988)a No increase in size during the pregnancy was observed in 25 fibroids (78%). Only 7 (22%) increased in size but by 
no more than 25% of the initial volume. At 6-week post-partum, the size of the fibroids did not differ significantly 
from the size during  pregnancyc
Rosati et al. (1992) A general increase in myoma size during the first trimester of pregnancy (especially before 10th week of gestation) 
and no evident enlargement during the remainder of the pregnancy were found, with a subsequent reduction in 
size during puerperium. No correlations between growth of myoma and their original size were  observedd
Neiger et al. (2006)a On average, there was no significant change in the size of leiomyomas during pregnancy. Size of myomas varied 
significantly during  pregnancyb
Hammoud et al. (2006) In the second trimester, 55.1% of myomas decreased in size (mean decrease in volume of 35%), while 44.9% 
of myomas enlarged (mean increase in volume of 69%). In the third trimester, the 75% became smaller (mean 
decrease in volume of 30%), while 25% enlarged (mean increase in volume of 102%). Mean diameter of 4 cm or 
more was highly predictive of size reduction during third trimester
Ozturk et al. (2009)a No enlargement of myomas was observed during  pregnancyc
Laughlin et al. (2010) 79% of myomas resulted smaller in puerperium in comparison to first measurement. Median diameter was subject 
to a median change of 0.5 cm. Submucous fibroid reduction (1.8 cm change) was higher than intramural (0.2 cm), 
subserous (0.6 cm), or pedunculated (0.5 cm) fibroids. Fibroids in the lower segment were associated with a 
greater change in fibroid diameter (1.4 cm) when compared to fibroids in the corpus (0.5 cm) or fundus (0.4 cm)b
De Vivo et al. (2011) 71.4% of uterine myomas grew between the first and second ultrasound and 28.6% remained unchanged or became 
smaller; the percentage of enlargement was slightly lower (66.6%) between the second and third investigations. 
Volumetric increase correlated negatively with multiparity and maternal age, respectively, between first and sec-
ond scan and the first and third  scand
Benaglia et al. (2014) A statistically significant increase of myoma size emerged in the pregnant group, with a median increase of diam-
eter of all the lesions of + 34%, whilst the median volume increase was + 140%b,d
Ciavattini et al. (2016) A volume increase of 122% was observed during the interval of the first to the second ultrasound, whereas a median 
growth of 108% was detected during the interval between the second and the third ultrasound and of 25% between 
the third and the fourth ultrasound. Smaller fibroids grew more frequently in comparison with larger ones A sig-
nificant positive correlation between hCG levels and diameter of myomas between 5 and 12 weeks  emergedb,d
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volume between 14 and 27 GW (+ 4.65%), which was not 
statistically significant.
Third trimester of pregnancy
Four studies investigated the modifications of UFs during 
the third trimester of pregnancy [15, 17–19]. Timing of UFs’ 
measurement was clearly described in three studies [15, 18, 
19].
In detail, Rosati et al. [15] observed a mean reduction in 
UFs volume of − 0.51% (± 4.16). Differently, Hammoud 
et al. [18] observed a pooled increase of UFs volume (from 
45.08 to 52.87 cm3), but the percentage of UFs enlarging 
was about 20% (mean increase in volume of 102%), with 
the majority of UFs (75%) reducing in size (about − 30% 
in pooled volume). Moreover, a major tendency to decrease 
in volume was observed in large UFs (88.1% of UFs with 
diameter > 4 cm), while small UFs (< 4 cm in diameter) 
mainly increased in size or showed no modifications (40% 
increased, 40% no change, and 20% decreased).
In the other hand, Lev-Toaff et al. [17] reported a main 
trend of reduction in size during the third trimester espe-
cially for large UFs (≥ 6 cm mean diameter), with 58.8% 
of lesions reducing in size (and remaining lesions showing 
no change). In addition, 34.8% of small UFs (< 6 cm mean 
diameter) reduced in size, and remaining UFs showed no 
change. Data about pooled modifications in size of UFs were 
not provided by Lev-Toaff et al. [17].
Finally, De Vivo et al. [19] reported a volumetric increase 
for 66.6% of UFs (between 20.6 and 33.1 GW), with a vol-
ume growth rate per week of 2%; such increase was slightly 
lower in comparison to the second trimester (between 11.6 
Fig. 2  Illustrative picture of 
main findings of the systematic 
review
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and 20.6 GW; 71.4% of UFs increase; 7.4% growth rate per 
week), but, however, significant (p = 0.03). No data about 
pooled volume/diameter were reported.
Overall modifications during pregnancy
Seven studies evaluated the modifications of UFs size during 
the entire course of pregnancy [10, 15, 20–24]. The timing 
of UFs measurements was inadequate/unclear in the major-
ity of studies [20–24], except in two studies [10, 15]. In 
Winer-Muram et al.’s study [21], the first US examination 
was performed between 10 and 20 GW, and Laughlin et al. 
[10] evaluated UFs enlargement from 6 to 7 GW to post-
partum, whilst in three additional studies [20, 22, 24], the 
time of the first UFs measurement was not clearly reported. 
Only Rosati et al. [15] and Neiger et al. [23] (data from 
meeting abstract) compared the final size of UFs with pre-
gestational size.
Rosati et al. [15] observed a significant mean increase of 
UFs’ volume from pre-gestational age to the end of preg-
nancy (11.85% ± 6.45), with a subsequent return to original 
size during puerperium, whilst Neiger et al. [23] reported 
no significant change in UFs size during the entire course 
of pregnancy. In Winer-Muram et al. study [21], there was 
no demonstrable change in the size of UFs in 82 patients 
(among 89 patients), while in 6 patients, there was an 
increase in size (by up to 4 cm in diameter), and in 1 patient, 
UF decreased by 2 cm in diameter. Similarly, Muram et al. 
[20] observed no modifications of UFs in 38 of 41 patients 
evaluated, whilst in the remaining three patients, a reduction 
(− 20%) of UFs diameter or an increase of UFs (+ 20 and 
+ 25% in diameter) was found. Accordingly, Ozturk et al. 
[22] reported no enlargement of UFs during pregnancy, as 
well as Aharoni et al. [24] mainly observed no size changes 
in the majority of UFs (78%) systematically measured, with 
only 7 UFs (22%) increasing in size (but by no more than 
25% of the initial volume).
Finally, Laughlin et al. [10] reported that 79% of Ufs 
resulted smaller in puerperium in comparison to first meas-
urement (performed at 8 GW), with greater reduction of 
submucous UFs in comparison to intramural and subserous 
UFs.
Puerperium
Only three studies published before 2000 [15, 21, 24] evalu-
ated the modifications of UFs size during puerperium. Clear 
data about the timing of UFs measurement were provided 
only by Rosati et al. [15], reporting a consistent reduction 
of UFs size during puerperium (− 12.87% ± 28.12 in mean 
volume). Winer-Muram et al. [21] observed a decrease in 
UFs diameter of at least 50% in all patients (n = 31) avail-
able for rescanning 6-week post-partum (quantitative data 
about UFs size not reported). Differently, Aharoni et al. [24] 
reported that 6 weeks after delivery the size of the fibroids 
did not differ significantly from the size during pregnancy 
(data from meeting abstract).
Assessment of the risk of study BIAS
All studies published exclusively in abstract form were 
considered at high risk of bias [22–24] (poor quality judge-
ment). Two additional studies of old publication date [20, 
21] were judged as qualitatively insufficient due to lack of 
study objectives explanation, absence of clear inclusion cri-
teria for patients’ enrollment, small sample size, and absence 
of inferential statistical analysis.
Five studies were considered as qualitatively fair [15–18]; 
however, concerns about their risk of bias were raised by the 
absence of clear inclusion criteria for patients’ enrollment 
in Rosati et al.’s study [15], the small sample size in three 
studies [15–17], the unclear/inconsistently delivery of UFs 
measurement across the study population in two studies [17, 
18], high percentage of loss to follow up (38,43%) in Laugh-
lin et al.’s study [10], and single assessment of UFs measures 
in four studies [10, 16–18].
Finally, two studies [9, 19] were considered at low risk 
of BIAS (good quality judgement), even if their results are 
potentially affected by single measurement of UFs size and 
by the small number of patients evaluated in De Vivo et al.’s 
experience [19]. Data are shown in Tables 3 and 4. 
Given the low number of studies included in each section, 
publication bias was not assessed.
Discussion
In line with the current trend of delaying childbearing, the 
frequency of pregnant women affected by UFs is signifi-
cantly increasing [9]. Although up to 70% of pregnancies 
conclude without complication, in the remaining situations, 
UFs may be responsible of a multitude of obstetrics prob-
lems, potentially occurring during each trimester of gesta-
tion [2, 4].
According to different authors, the risk of UF-related 
complications during pregnancy might be primarily cor-
related with the size of lesions, while the exact localiza-
tion of tumors (submucosal, intramural, or subserosal) 
may be responsible for different, specific kinds of adverse 
events [8, 25, 26]. Anyhow, UFs may be frequently sub-
ject to significant volumetric modifications during gesta-
tion. It complicates the clinical management of patients 
affected by UFs [1, 13, 27]. Moreover, basing on the cur-
rent knowledge, physicians are not able to inform patients 
about the real likelihood of UFs to persist, regress, or 
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even increase in volume after the completion of preg-
nancy, inducing to postpone each clinical consideration 
after puerperium [6, 16].
Main findings
In spite of the abundance of scientific manuscripts specu-
lating about diagnosis, medical, and surgical treatment of 
Table 3  Quality assessment of the studies according to “Quality Assessment Tool for Before–After (Pre–Post) Studies with no Control Group”
Study ID
Muram 
et al.
(1980)
Winer-
Muram 
et al.
(1983)
Lev-
Toaff 
et al.
(1987)
Aharoni 
et al.
(1988)
Rosati 
et al.
(1992)
Neiger 
et al.
(2006)
Hammoud 
et al.
(2006)
Ozturk 
et al.
(2009)
Laughlin 
et al.
(2010)
Vivo 
et al.
(2011
)
Benaglia 
et al.
(2014)
Ciavattini 
et al.
(2016)
1) Was the study objective 
clearly stated?
2) Were selection criteria for 
the study population 
prespecified and clearly 
described?
3) Were the participants in 
the study representative 
of those who would be 
eligible for the test in the 
general population of 
interest?
4) Were all eligible 
participants that met the 
prespecified entry criteria 
enrolled?
5) Was the sample size 
sufficiently large to 
provide confidence in the 
findings?
6) Was the test clearly 
described and delivered 
consistently across the 
study population?
7) Were the outcome 
measures prespecified, 
clearly defined, valid, 
reliable, and assessed 
consistently across all 
study participants?
8) Were the people 
assessing the outcomes 
blinded to the 
NO
NO
NR
NR
NO
YES
YES
NA
NO
NO
NR
NR
NO
YES
YES
NA
YES
YES
NR
YES
NO
NO
YES
NA
NR
NR
NR
NR
NR
NR
NR
NA
YES
NO
NR
NR
NO
YES
YES
NA
NR
NR
NR
NR
NR
NR
NR
NA
YES
YES
YES
YES
YES
NR
YES
NA
NR
NR
NR
NR
NR
NR
NR
NA
YES
YES
YES
NO
YES
YES
YES
NA
YES
YES
YES
YES
NO
YES
YES
NA
YES
YES
NO
YES
NO
YES
YES
NA
YES
YES
YES
YES
YES
YES
YES
NA
Quality rating criteria: POOR: < 4 points; FAIR: ≥ 4–8 points; GOOD: > 8 points
NA not applicable, NR not reported
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UFs [28–31], our review revealed an unexpected paucity 
of data about the growth pathway of such lesions during 
pregnancy.
Concerning the first trimester of pregnancy, all authors [9, 
15–17] reported a significant growth of UFs. These results 
are supported by adequate evidence quality (four studies 
[9, 15–17] with fair/good quality judgement including 218 
UFs), suggesting that UFs are likely to grow in the first tri-
mester of gestation. However, the magnitude of UFs enlarge-
ment was not quantifiable due to heterogeneity in outcome 
measures.
Differently, despite the overall evidence quality was fair/
good, we found contradictory data about the modifications 
of UFs during the second trimester of pregnancy. In detail, 
if two studies [9, 19] found a prevalent growing trend of UFs 
during such period (even if slower in comparison to the trend 
reported during the first trimester in Ciavattini et al.’s study 
[9]), two other studies [17, 18] reported a variable trend of 
growth of UFs, with approximately half growing and half 
reducing in size. Finally, Rosati et al. [15] observed no sig-
nificant change in UFs’ volume.
Such inconsistency of findings may be attributable to the 
heterogeneity of studies in terms of chronological realiza-
tion (from 1987 to 2016), timing of US examinations and/
or study populations, or perhaps may support a non-linear 
trend of growth of UFs during the second trimester of preg-
nancy. To further stress the last hypothesis, we noted that 
the authors reporting a mean increase in UFs size [9, 19] 
performed US measurements earlier (11.6–20.6 GWs and 
10–13 to 20–22 GW, respectively) in comparison with the 
authors [15, 17, 18] reporting different results (14–27 GWs 
and 16–19 to 20–30 GWs, respectively). This suggests that 
UFs may undergo a progressive slowdown during the second 
trimester [9], up to stabilization and a subsequent regression 
[17, 18]. In addition, as suggested by two studies [17, 19], 
some UFs may start to reduce in size earlier (at the begin-
ning of the second trimester) and other significantly later 
(during the second half of gestation), probably in relation 
to their initial size (with larger lesions starting to reduce in 
size earlier in comparison to smaller lesions). Nevertheless, 
in the absence of consistent evidence, UFs modifications 
during the second trimester need further clarification.
Similarly, available evidence (supported by studies with 
fair/good quality) does not allow a clear appreciation of the 
modifications of UFs during the third trimester. A significant 
size reduction was reported by two studies [15, 17], while 
Hammoud et al. [18] observed that UFs mainly reduced in 
size if larger than 4 cm (in diameter) and enlarged/did not 
change if smaller than 4 cm (in diameter). Differently, De 
Vivo et al. [19] found a significant increase in UFs volume 
in comparison to the previous US evaluation (performed 
between 11.6 and 20.6 GWs).
As well as for data showed about the second trimester, a 
chronological difference in UFs measurements was present 
Table 4  Authors’ judgement of study quality and fibroids’ modifications reported by each single study
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among studies. Such difference may hypothetically explain 
the inconsistency between results provided by De Vivo et al. 
[19] (first US scan performed earlier, see Fig. 2) and those 
reported by other authors [15, 17, 18]. However, even if UFs 
seem to be more likely to reduce their volume during the 
third trimester, such speculation needs to be clearly con-
firmed by further studies [8, 18].
Concerning the overall modifications of UFs during preg-
nancy and puerperium, the quality of available evidence is 
poor; indeed, the majority of studies were judged at high risk 
of bias [20–24], except Rosati et al. [15] and Laughlin et al. 
[10] studies. In addition, some concerns are present about 
the timing of UFs measurements (unclear of inadequate in 
the majority of studies [10, 20–24]). In particular, regard-
ing the overall changes of UFs in pregnancy, the majority of 
the authors reported no modifications [20–24] except Rosati 
et al. [15], who reported a mean increase in UFs volume 
in comparison to pre-pregnancy measurement. Differently, 
regarding the modifications of UFs during puerperium, all 
studies reported a size reduction [15, 21] or no changes [24]. 
Therefore, even if available data mainly suggest that UFs 
do not modify their volume/slightly enlarge during preg-
nancy and subsequently reduce in size during puerperium, 
adequate evidence quality is needed to clarify the topic.
Implications
The hormonal and molecular mechanisms involved in UFs 
modifications during pregnancy are unclear and will rep-
resent a challenging field of research. At this regard, some 
authors argued that the remarkable growth of UFs during the 
initial pregnancy could be related to other pregnancy-related 
hormones rather than sex steroids [19]; indeed, serum con-
centrations of estrogen and progesterone are conversely 
higher in the second half of pregnancy [9, 16]. In particular, 
an exciting hypothesis is the “LH-hCG myomal receptors 
hyperstimulation” due to serum embryonic-hCG increase in 
the early gestation; such speculation is supported by a recent 
clinical study showing a statistical correlation between 
UFs enlargement (in volume) and exponential growth of 
hCG during the first trimester of gestation [9]. In addition, 
in vitro studies found that the exposition of leiomyomal cells 
to exponentially increasing concentrations of hCG results 
in dramatic hypertrophic and hyperplastic changes, with a 
progressive decrease in modifications as the culture period 
progressed [32–34]. This time-limited stimulating effect of 
hCG may also insightfully explain the progressive slowdown 
of UFs observed by different authors during the second tri-
mester [15, 17]. Nevertheless, given the possible histologi-
cal heterogeneity of UFs in terms of percentages of smooth 
muscle cells and collagenous matrix, it is possible that the 
expression of LH receptors may be different from myoma 
to myoma, leading to a wide range of sensitivity to hCG 
stimulation [16, 33, 34].
However, besides the interesting hypothesis about hCG-
driven UFs growth, a plethora of other hormones, enzymes, 
and growth factors secreted by the maternal and feto-placen-
tal compartments markedly increase during the early preg-
nancy [35]. We cannot exclude that such molecules may 
exert a concomitant effect on fibroid growth, as the potential 
effects of all these substances have not been systematically 
investigated. Similarly, other factors such as myoma–pla-
cental site relationship and UFs location (submucosal, intra-
mural, or subserosal) may somehow influence their growth 
trend [8, 10, 13, 19].
Limits
The results of our review are limited by the features of 
included studies, such as study quality (five of 12 studies 
judged as qualitatively poor) and design (mainly retrospec-
tive), small sample size, lapse of time in study realization 
(from 1987 to 2016), and different methodology (ultrasound 
equipment, expertise of sonographers, gestational age at UFs 
measurements, and racial characteristics of populations). 
Moreover, a quantitative data synthesis was not performed 
(due to significant heterogeneity among studies in outcome 
measures and in timing of UFs measurements), limiting 
the robustness of our findings. Finally, the assessment of 
UFs through US, although validated in clinical practice, is 
exposed to a certain degree of inaccuracy in relation to UFs 
diagnosis (lacking of histological confirmation) and meas-
urements [9, 16, 18, 36].
Conclusions
UFs seem to be subject to a non-linear trend of modifica-
tions UFs during pregnancy and puerperium, which may 
vary from myoma to myoma (both in terms of timing and 
quality of changes). Approximately, fibroids may undergo 
an intriguing “triphasic trend” of changes during pregnancy, 
with a first phase of enlargement during the first trimester, 
an intermediate stage of slowdown and stabilization during 
the second trimester, and a third phase of volume regres-
sion during late pregnancy and puerperium. In particular, 
adequate evidence supports UFs systematic enlargement 
during the first trimester of pregnancy. Differently, few data 
are available about the changes of UFs during second and 
third trimesters, as well as poor evidence is available about 
the overall modifications of such tumors during pregnancy 
and puerperium. Moreover, the impact of UFs characteristics 
(size, position, and subtype) and patients features (ethnicity 
and parity) on UFs changes needs to be further investigated 
[36–38].
 Archives of Gynecology and Obstetrics
1 3
Our study provides the first summary of evidence about 
the modifications of UFs during pregnancy and puerper-
ium, highlighting the existing deficiencies in the literature 
on this topic. Given the plethora of clinical–pathological 
implications of UFs growth during pregnancy, the present 
manuscript will figure as “eye opener” to scientists about the 
necessity of further research on this topic. Clear evidence is 
needed to allow a more conscious clinical management, as 
well as appropriate counseling of pregnant patients suffering 
from UFs. Adequately powered prospective studies com-
prising seriated UFs measurements from pre-conceptional 
period (and during the whole pregnancy) to puerperium are 
mandatory to clarify the issue.
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